GlaxoSmithKline Consumer Healthcare Ltd. said its normalized net income for the fiscal fourth quarter ended March 31 came to 45.54 Indian rupees per share, compared with the S&P Capital IQ consensus estimate of 48.27 rupees per share.
EPS climbed 16.4% year over year from 39.13 rupees.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was 1.92 billion rupees, a gain of 16.4% from 1.65 billion rupees in the prior-year period.
The normalized profit margin rose to 14.3% from 13.0% in the year-earlier period.
Total revenue rose 5.7% year over year to 13.36 billion rupees from 12.65 billion rupees, and total operating expenses grew on an annual basis to 10.87 billion rupees from 10.47 billion rupees.
Reported net income rose 14.6% on an annual basis to 1.97 billion rupees, or 46.79 rupees per share, from 1.72 billion rupees, or 40.83 rupees per share.
For the year, the company's normalized net income totaled 133.35 rupees per share, compared with the S&P Capital IQ consensus normalized EPS estimate of 143.87 rupees.
EPS rose 13.5% from 117.48 rupees in the prior year.
Normalized net income was 5.61 billion rupees, a rise of 13.5% from 4.94 billion rupees in the prior year.
Full-year total revenue rose 9.6% from the prior-year period to 43.08 billion rupees from 39.29 billion rupees, and total operating expenses rose 9.6% year over year to 36.29 billion rupees from 33.10 billion rupees.
The company said reported net income rose 12.6% year over year to 5.84 billion rupees, or 138.77 rupees per share, in the full year, from 5.18 billion rupees, or 123.25 rupees per share.
As of July 10, US$1 was equivalent to 63.32 Indian rupees.